Novel Agents and Future Perspectives on Theranostics

Lilja B. Solnes, Monica Shokeen, Neeta Pandit-Taskar

Research output: Contribution to journalReview articlepeer-review

Abstract

In the current era of precision medicine, there is renewed interest in radiopharmaceutical therapy and theranostics. The approval of somatostatin receceptor directed therapy and norepinephrine transporter targeted 131I-MIBG therapies by the FDA and the rapid progress of highly promising beta and alpha emitter tagged PSMA directed therapy of prostate cancer have stimulated clinically impactful changes in practice. Many novel strategies are being explored and novel radiopharmaceutical therapeutic agents including peptide based ligands as well as antibodies or antibody fragments are being developed preclinically or are in early phase clinical trials. While beta particle emitters have most commonly been used for targeted radiotherapy and radioimmunotargeting, there is an emerging interest in alpha emitters that cause greater density of ionization events leading to increased double-strand DNA damage and cluster breaks because of the high-energy particles within a shorter tissue range of penetration and thereby lower toxicity to adjacent normal tissues.

Original languageEnglish (US)
Pages (from-to)83-92
Number of pages10
JournalSeminars in Radiation Oncology
Volume31
Issue number1
DOIs
StatePublished - Jan 2021

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Novel Agents and Future Perspectives on Theranostics'. Together they form a unique fingerprint.

Cite this